BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that its review of the Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies will not be completed by the Prescription Drug User Fee Act (PDUFA) action date o

Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, presents new preliminaryclinical data from a Phase I/IIa study of Temferon in patients affected by glioblastoma multiforme at the 2020 Society for Neuro-Oncology Annual Meeting, taking place November 19-22 in Austin, TX.

New March Of Dimes Report Card Shows Preterm Birth Rates Climb For 5th Straight Year, Earning The Nation A “C-" Grade Humana Foundation and March of Dimes are partnering in six communities nationwide to implement strategies to improve maternal and infant health

Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of Lupin Limited, announced that the U.S. Food and Drug Administration has accepted their supplemental New Drug Application for Solosec® for the treatment of trichomoniasis in adults and adolescents.

Cytiva provides FlexFactory™ bioprocessing upstream and downstream solutions for Clover to accelerate GMP facility development and shorten time to market

Patient Blood Management with Masimo SpHb Increased Transfusion Appropriateness and Decreased RBC Units Transfused per Patient

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases, announced the appointment of Bryan Yoon as Chief Operating Officer and General Counsel.

iSTAR Medical, a medtech company developing minimally invasive ophthalmic implants for treatment of patients with glaucoma, announced positive one-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery device, MINIjectTM.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced milestones for patents and grants on both its lead drug candidates Nyxol and APX3330.